These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28343336)

  • 21. [Therapeutic significance of sunitinib-induced "off-target" side effects].
    Maráz A; Cserháti A; Uhercsák G; Szilágyi E; Varga Z; Kahán Z
    Magy Onkol; 2014 Sep; 58(3):167-72. PubMed ID: 25260080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.
    Nearchou A; Valachis A; Lind P; Akre O; Sandström P
    Clin Genitourin Cancer; 2015 Aug; 13(4):280-286. PubMed ID: 25442773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
    Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
    Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
    Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
    Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
    Kust D; Prpić M; Murgić J; Jazvić M; Jakšić B; Krilić D; Bolanča A; Kusić Z
    Anticancer Res; 2014 Jun; 34(6):3177-84. PubMed ID: 24922691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study.
    Miyake M; Kuwada M; Hori S; Morizawa Y; Tatsumi Y; Anai S; Hosokawa Y; Hayashi Y; Tomioka A; Otani T; Otsuka K; Nakagawa Y; Nakai Y; Samma S; Tanaka N; Fujimoto K
    BMC Res Notes; 2016 Feb; 9():79. PubMed ID: 26861149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
    Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.
    Coelho RC; Reinert T; Campos F; Peixoto FA; de Andrade CA; Castro T; Herchenhorn D
    Int Braz J Urol; 2016; 42(4):694-703. PubMed ID: 27564279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
    Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
    Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
    Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
    Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.